BigHat Biosciences

BigHat Biosciences is a private, Series B biotech company leveraging a proprietary integrated platform called Milliner to revolutionize antibody discovery and engineering. The platform synergizes high-throughput synthetic biology labs with advanced machine learning models to design, build, and test hundreds of antibody variants weekly, significantly compressing development timelines. The company has a pipeline of over ten therapeutic programs, engages in strategic partnerships with major pharma, and has raised over $100 million from top-tier investors to advance its mission of creating better biologics faster.

Milliner platform: A full-stack, integrated system combining a high-speed synthetic biology wet lab for antibody synthesis and characterization with machine learning models (including protein language models) to guide the design of improved therapeutic antibodies in rapid design-build-test-learn cycles.

BigHat competes in the rapidly growing field of AI/ML-driven drug discovery, facing competition from other biotechs like Absci, Generate Biomedicines, and Recursion, as well as internal efforts at large pharmaceutical companies. Its differentiation lies in its tightly integrated full-stack platform that combines proprietary wet-lab throughput with specialized ML models for antibodies.